MannKind Corporation develops patient-focused drug therapies and innovative technology solutions.
We specialize in innovative technologies with proven ease-of-use and patient acceptance.
Needle-free, self-administered Inhalation Treatment Systems for both chronic and acute diseases.
Our Technosphere® technology can accommodate a wide variety of APIs required by specific drug therapies.
MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. More
|Nov 06, 2019||MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results… More|
|Nov 04, 2019||MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics… More|
|Oct 30, 2019||MannKind Corporation to Hold 2019 Third Quarter Financial Results Conference Call on November 6, 2019… More|
|Sep 26, 2019||MannKind Corporation to Present at the 2019 Cantor Global Healthcare Conference… More|
If you are reporting an Adverse Event and/or device complaint, please contact MannKind Medical Information at 1-877-323-8505 or MannKind@druginfo.com. Do not use this form for adverse events and/or device complaints.